SCHEMBL3018660

SCHEMBL3018660

Cc1cccc(C)c1-c1csc(N2CCC(S(=O)(=O)c3ccc(CBr)cc3)CC2)n1

nearest known ligand 0.43

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 10/20 0.41
RAB9A P51151 6/20 0.41
NPC1 O15118 5/20 0.41
KMT2A Q03164 3/20 0.40
MEN1 O00255 2/20 0.40
LMNA P02545 1/20 0.40
MAPK1 P28482 1/20 0.40
GBA1 P04062 1/20 0.37
ALDH1A1 P00352 1/20 0.37
CYP1A2 P05177 1/20 0.37
POLB P06746 1/20 0.37
MAPT P10636 1/20 0.37
CYP2C9 P11712 1/20 0.37
HPGD P15428 1/20 0.37
CYP2C19 P33261 1/20 0.37
HTT P42858 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3020041 0.91 SMN1; SMN2 (0.40) SMN1; SMN2RAB9ANPC1KMT2AMEN1
SCHEMBL3017829 0.90 AR (0.39) SMN1; SMN2RAB9ANPC1KMT2AMEN1
SCHEMBL3007187 0.89 SMN1; SMN2 (0.42) SMN1; SMN2RAB9ANPC1KMT2AMEN1
SCHEMBL3018817 0.89 SMN1; SMN2 (0.48) SMN1; SMN2RAB9ANPC1KMT2AMEN1
SCHEMBL3012023 0.89 SMN1; SMN2 (0.50) SMN1; SMN2RAB9ANPC1KMT2AMEN1
SCHEMBL3007141 0.87 SMN1; SMN2 (0.49) SMN1; SMN2RAB9ANPC1KMT2AMEN1
SCHEMBL3015756 0.87 SMN1; SMN2 (0.45) SMN1; SMN2RAB9ANPC1KMT2AMEN1
SCHEMBL3002767 0.86 SMN1; SMN2 (0.47) SMN1; SMN2RAB9ANPC1KMT2AMEN1
SCHEMBL3015149 0.85 SMN1; SMN2 (0.54) SMN1; SMN2RAB9ANPC1KMT2AMEN1
SCHEMBL3009914 0.85 SMN1; SMN2 (0.52) SMN1; SMN2RAB9ANPC1LMNAMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA SMN1; SMN2 1/4885RAB9A 2943/4885NPC1 15/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.